Gastrointestinal Manifestations of Coronavirus Disease 2019 Across the United States: A Multicenter Cohort Study.
ALT, alanine aminotransferase
AST, aspartate aminotransferase
BMI, body mass index
CI, confidence interval
COVID-19
COVID-19, coronavirus disease 2019
Coronavirus Disease 2019
GI, gastrointestinal
Gastrointestinal
ICU, intensive care unit
OR, odds ratio
SARS-CoV-2
SD, standard deviation
UCLA, University of California Los Angeles
aOR, adjusted odds ratio
Journal
Gastro hep advances
ISSN: 2772-5723
Titre abrégé: Gastro Hep Adv
Pays: Netherlands
ID NLM: 9918350485906676
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
06
2022
accepted:
06
07
2022
pubmed:
26
7
2022
medline:
26
7
2022
entrez:
25
7
2022
Statut:
ppublish
Résumé
Gastrointestinal (GI) symptoms occur among patients diagnosed with coronavirus disease 2019 (COVID-19), and there is clear evidence that SARS-CoV-2, the causative pathogen, infects the GI tract. In this large, multicenter cohort study, we evaluated variations in gastrointestinal and hepatic manifestations of COVID-19 throughout the United States (US). Patients hospitalized with a positive COVID-19 test prior to October 2020 were identified at 7 US academic centers. Demographics, presenting symptoms, laboratory data, and hospitalization outcomes were abstracted. Descriptive and regression analyses were used to evaluate GI manifestations and their potential predictors. Among 2031 hospitalized patients with COVID-19, GI symptoms were present in 18.9%; diarrhea was the most common (15.2%), followed by nausea and/or vomiting (12.6%) and abdominal pain (6.0%). GI symptoms were less common in the Western cohort (16.0%) than the Northeastern (25.6%) and Midwestern (26.7%) cohorts. Compared to nonintensive care unit (ICU) patients, ICU patients had a higher prevalence of abnormal aspartate aminotransferase (58.1% vs 37.3%; We present the largest multicenter cohort of patients with COVID-19 across the United States. GI manifestations were common among patients hospitalized with COVID-19, although there was significant variability in prevalence and predictors across the United States.
Sections du résumé
Background and Aims
UNASSIGNED
Gastrointestinal (GI) symptoms occur among patients diagnosed with coronavirus disease 2019 (COVID-19), and there is clear evidence that SARS-CoV-2, the causative pathogen, infects the GI tract. In this large, multicenter cohort study, we evaluated variations in gastrointestinal and hepatic manifestations of COVID-19 throughout the United States (US).
Methods
UNASSIGNED
Patients hospitalized with a positive COVID-19 test prior to October 2020 were identified at 7 US academic centers. Demographics, presenting symptoms, laboratory data, and hospitalization outcomes were abstracted. Descriptive and regression analyses were used to evaluate GI manifestations and their potential predictors.
Results
UNASSIGNED
Among 2031 hospitalized patients with COVID-19, GI symptoms were present in 18.9%; diarrhea was the most common (15.2%), followed by nausea and/or vomiting (12.6%) and abdominal pain (6.0%). GI symptoms were less common in the Western cohort (16.0%) than the Northeastern (25.6%) and Midwestern (26.7%) cohorts. Compared to nonintensive care unit (ICU) patients, ICU patients had a higher prevalence of abnormal aspartate aminotransferase (58.1% vs 37.3%;
Conclusion
UNASSIGNED
We present the largest multicenter cohort of patients with COVID-19 across the United States. GI manifestations were common among patients hospitalized with COVID-19, although there was significant variability in prevalence and predictors across the United States.
Identifiants
pubmed: 35874930
doi: 10.1016/j.gastha.2022.07.002
pii: S2772-5723(22)00116-9
pmc: PMC9293374
doi:
Types de publication
Journal Article
Langues
eng
Pagination
909-915Subventions
Organisme : NIDDK NIH HHS
ID : K23 DK119544
Pays : United States
Informations de copyright
© 2022 The Authors.
Références
Sci Rep. 2021 Jun 25;11(1):13308
pubmed: 34172783
Gastroenterology. 2020 Sep;159(3):1137-1140.e2
pubmed: 32389667
Sci Immunol. 2020 May 13;5(47):
pubmed: 32404436
J Med Virol. 2021 May;93(5):2740-2768
pubmed: 33527440
Dis Mon. 2020 Sep;66(9):101064
pubmed: 32807535
J Gastroenterol. 2021 May;56(5):409-420
pubmed: 33759041
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
PLoS Biol. 2018 Dec 4;16(12):e2006842
pubmed: 30513082
BMJ Open Gastroenterol. 2021 Mar;8(1):
pubmed: 33664052
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Front Microbiol. 2017 Jun 23;8:1162
pubmed: 28690602
Gastroenterology. 2020 Aug;159(2):765-767.e2
pubmed: 32333911
Gastroenterology. 2021 Jun;160(7):2435-2450.e34
pubmed: 33676971
Nature. 2016 Jul 21;535(7612):435-439
pubmed: 27409808
Front Artif Intell. 2021 Aug 18;4:680564
pubmed: 34490420
Gastroenterology. 2020 Aug;159(2):775-777
pubmed: 32283101
Gastroenterology. 2020 Jul;159(1):81-95
pubmed: 32251668
J Clin Gastroenterol. 2021 Jan;55(1):67-76
pubmed: 33116063
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210